LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Laboratoires Théa for the Canadian market, focusing on the eye drop treatment LNZ100 for presbyopia. The agreement secures over $70 million in upfront and milestone payments for LENZ, along with double-digit royalties on net sales. Théa, a prominent company in eye-care product commercialization, will handle the development, manufacturing, registration, and marketing of LNZ100 in Canada. This partnership marks LENZ's third international commercialization deal for LNZ100, underscoring its commitment to broadening patient access to this innovative therapy globally. Jean-Frédéric Chibret, President of Théa, highlighted the potential of this promising treatment to address a widespread condition affecting millions of adults in Canada.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。